UK markets open in 7 hours 12 minutes
NIKKEI 225
38,274.05 -131.61 (-0.34%) HANG SENG
17,763.03 +16.12 (+0.09%) CRUDE OIL
79.06 +0.06 (+0.08%) GOLD FUTURES
2,330.80 +19.80 (+0.86%) DOW
37,903.29 +87.37 (+0.23%) Bitcoin GBP
46,592.85 -1,867.95 (-3.85%)
Merck & Co., Inc. (0QAH.IL)
IOB - IOB Delayed price. Currency in USD
Add to watchlist
At close: 07:10PM BST
| Previous close | 130.00 |
| Open | 0.00 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 200,431 |
| Market cap | 327.34B |
| Beta (5Y monthly) | 0.38 |
| PE ratio (TTM) | 105.74 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.92 (2.83%) |
| Ex-dividend date | 14 Sept 2023 |
| 1y target est | N/A |
- Business Wire
Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
RAHWAY, N.J., May 01, 2024--Merck Announces KEYNOTE-811 Trial Met Dual Primary Endpoint as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or GEJ Cancer
- Business Wire
Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
RAHWAY, N.J., April 29, 2024--Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
- Business Wire
Merck Announces First-Quarter 2024 Financial Results
RAHWAY, N.J., April 25, 2024--Merck Announces First-Quarter 2024 Financial Results
© 2024 Yahoo. All rights reserved.